COVID-19 in multiple sclerosis patients and risk factors for severe infection
This article has been Reviewed by the following groups
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
- 
  
- 
      SciScore for 10.1101/2020.05.27.20114827: (What is this?) Please note, not all rigor criteria are appropriate for all manuscripts. Table 1: Rigor Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources No key resources detected. Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog). 
 Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:A significant limitation to our study is the relatively small sample size collected; therefore risk-stratification adjusting for confounders was not possible. Larger studies are therefore required in order to improve for … SciScore for 10.1101/2020.05.27.20114827: (What is this?) Please note, not all rigor criteria are appropriate for all manuscripts. Table 1: Rigor Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources No key resources detected. Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog). 
 Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:A significant limitation to our study is the relatively small sample size collected; therefore risk-stratification adjusting for confounders was not possible. Larger studies are therefore required in order to improve for confounding variables. Also, there was a significant discrepancy in sample-size for each course, as there were only 6 patients with severe disease course. Therefore, significant differences may not have been detected in post hoc comparisons with this course. Regardless, we showed that certain MS-characteristics were more frequent in more COVID-19 severe courses. Results from TrialIdentifier: No clinical trial numbers were referenced. Results from Barzooka: We did not find any issues relating to the usage of bar graphs. Results from JetFighter: We did not find any issues relating to colormaps. 
 Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
 
- 
    
